Related Articles
XELIRI compared with FOLFIRI as a second‑line treatment in patients with metastatic colorectal cancer
Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI
Irinotecan, leucovorin and 5‑fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer
ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX‑based neoadjuvant concurrent chemoradiation